Scientists Discover Key Alzheimer's Tipping Point in Microglia That May Determine Who Gets Dementia
Key Insights
A new study in Nature Medicine identifies a critical biological transition in microglia, the brain's immune cells, that may separate Alzheimer's pathology from progression to dementia.
Researchers mapped six distinct tissue states and found microglia switch from an early inflammatory response to a later antigen-presenting state coinciding with tau pathology and neurodegeneration.
Cognitively resilient octogenarians showed early microglial responses without transitioning to the later disease-linked state, while centenarians activated the later program independently of tau accumulation.
A landmark study published in Nature Medicine has uncovered a crucial biological tipping point in the brain's immune cells that may explain why some individuals accumulate Alzheimer's pathology yet never develop dementia, while others experience progressive cognitive decline.
The research, led by scientists from VIB, KU Leuven, the UK Dementia Research Institute (search) (UK-DRI), and Muna Therapeutics (search), identifies dramatic shifts in microglia—the brain's resident immune cells—as a potential driver of this divergence. The findings open new therapeutic avenues that extend beyond the traditional focus on amyloid plaque removal.
"This has been an exciting journey with many partners. The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia," said Prof. Bart De Strooper (VIB-KU Leuven (search) Center for Neuroscience, KU Leuven), ERC grantee and co-senior author of the study.
Mapping the Cellular Landscape of Alzheimer's Progression
Using spatial transcriptomics and single-cell sequencing—technologies that enable gene activity analysis at the level of individual cells while preserving their anatomical context—the research team identified six distinct tissue states corresponding to different stages of Alzheimer's disease (search).
A key turning point emerged between tissue domains associated primarily with amyloid-β plaques and those linked to tau pathology and neurodegeneration. Early disease stages were characterized by amyloid plaque accumulation and an inflammatory microglial response. As the disease advanced, microglia underwent a fundamental transformation, switching to a distinct antigen-presenting state that appeared alongside the emergence of tau pathology.
The researchers believe this cellular transition may represent a critical step determining whether Alzheimer's pathology ultimately progresses toward dementia.
"Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia," said Prof. Mark Fiers (VIB-KU Leuven (search)), co-senior author of the study.
Two Distinct Routes to Cognitive Resilience
One of the study's most striking discoveries was that resilience to Alzheimer's pathology appears to emerge through more than one biological mechanism.
Among octogenarians who had accumulated amyloid plaques but remained cognitively healthy, microglia entered the early inflammatory state but never made the transition to the later immune program linked to disease progression. In contrast, centenarians—individuals over 100 years of age—presented a different pattern: their brains activated the later microglial state, but this response occurred largely independently of tau accumulation.
This suggests that resilience is not simply the absence of disease-related changes. Rather, the brain may be capable of rewiring or reshaping its response to pathology in ways that preserve cognitive function. A cellular state linked to neurodegeneration in some individuals appeared to be uncoupled from harmful effects in others.
Therapeutic Implications and the TREM2 Pathway
The findings arrive at a pivotal moment in Alzheimer's drug development. While recent therapies have succeeded in removing amyloid plaques from the brain, their effects on slowing cognitive decline have generally been modest. The new results suggest that targeting the brain's immune response could be equally important.
Rather than focusing exclusively on eliminating plaques, future treatments may aim to preserve beneficial microglial activity or prevent the cellular transition associated with disease progression. The researchers specifically highlight pathways involving TREM2 (search), a gene already linked to Alzheimer's risk and microglial function, as a promising area for further investigation.
The study also points to a potentially narrow therapeutic window. Intervening before inflammatory responses become tightly connected to tau pathology may offer the best chance of preserving brain function.
"These findings open new opportunities to target microglial states, especially pathways such as TREM2 (search), and extend resilience rather than simply focusing on plaque removal. We are excited to continue this journey and understand the causal role of microglial transitions leading to the identification of novel therapeutic approaches to delay or prevent disease progression," said Niels Plath, Chief Scientific Officer of Muna Therapeutics (search).
Alzheimer's disease (search) affects more than 55 million people worldwide, making it the most common cause of dementia. The study, published on June 4, 2026, was supported by Muna Therapeutics (search), VIB, KU Leuven, the European Research Council (ERC), the UK-DRI, and the Research Foundation Flanders (FWO).